P
Philippe Steg
Researcher at Brigham and Women's Hospital
Publications - 19
Citations - 600
Philippe Steg is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Ticagrelor & Clopidogrel. The author has an hindex of 7, co-authored 19 publications receiving 567 citations. Previous affiliations of Philippe Steg include University of Sheffield & University of Florida.
Papers
More filters
Journal ArticleDOI
Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis
Philippe Steg,Stefan James,Robert A. Harrington,Diego Ardissino,Richard C. Becker,Christopher P. Cannon,Håkan Emanuelsson,Ariel Finkelstein,Steen Husted,Hugo Katus,Jan Kilhamn,Sylvia Olofsson,Robert F. Storey,W. Douglas Weaver,Lars Wallentin +14 more
TL;DR: Ticagrelor, a reversible oral P2Y12-receptor antagonist, provides faster, greater, and more consistent platelet inhibition than clopidogrel and may be useful for patients with acute ST-segment elevation (STE) ACS and planned primary percutaneous coronary intervention as discussed by the authors.
Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial Impact clinique de l'arrêt définitif du clopidogrel ou du placebo dans l'étude CHARISMA
Jean-Philippe Collet,Gilles Montalescot,Philippe Steg,Steven R. Steinhubl,S. Claiborne Johnston,Christian Hamm,Deepak L. Bhatt,Eric J. Topol +7 more
TL;DR: In this article, the authors describe the characteristics and evolution of patients non-compliant to study drug in the prospective, randomized, double-blind CHARISMA trial and conclude that patients who stopped medication had increased rates of ischaemic and bleeding events and mortality.
Journal ArticleDOI
Efficacy and safety of ticagrelor as long-term secondary prevention in patients with prior myocardial infarction and peripheral artery disease
Marc P. Bonaca,Deepak L. Bhatt,Robert F. Storey,Philippe Steg,Marc Cohen,Julia F Kuder,KyungAh Im,Peter Held,Eva C. Jensen,Eugene Braunwald,Marc S. Sabatine +10 more
TL;DR: PEGASUS-TIMI 54, a contemporary trial of pts with prior MI, evaluated ischemic and bleeding risk by concomitant PAD and whether the efficacy and safety of ticagrelor was modified by PAD.
Journal ArticleDOI
Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the champion trials
Dominick J. Angiolillo,Deepak L. Bhatt,Philippe Steg,Gregg W. Stone,Harvey White,C. Michael Gibson,Christian Hamm,Matthew J. Price,Jayne Prats,Tiepu Liu,Jonathan F. Day,Kenneth W. Mahaffey,Robert A. Harrington +12 more
TL;DR: Cangrelor is a potent intravenous platelet P2Y12 receptor with rapid onset and offset of action that reduces periprocedural thrombotic complications in patients undergoing percutaneous bleeding.
Journal ArticleDOI
Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)
Elliott M Groves,Deepak L. Bhatt,Philippe Steg,Efthymios Deliargyris,Gregg W. Stone,C. Michael Gibson,Christian Hamm,Kenneth W. Mahaffey,Harvey White,Dominick J. Angiolillo,Jayne Prats,Robert A. Harrington,Matthew J. Price +12 more
TL;DR: Acquired thrombocytopenia after PCI is strongly associated with substantial early morbidity and mortality, as well as major bleeding, and Cangrelor is not associated with acquired thromBocy topenia, and its clinical efficacy and safety is consistent irrespective of throm bocytopania occurrence.